Food Allergy
Dbv Technologies focuses on peanut allergy, with clinical research centered on improving desensitization and long-term management in children affected by this IgE-mediated allergy.
- Peanut allergy
- Food allergen immunotherapy
- Allergic disease in children
The sponsor’s research activity includes studies in young pediatric populations, reflecting a strong interest in early-life allergy care and the clinical handling of persistent food hypersensitivity.
Epicutaneous Immunotherapy
Its clinical program is built around epicutaneous immunotherapy for peanut allergy, using skin-based exposure approaches aimed at reducing allergic reactivity and supporting sustained treatment benefit.
- Epicutaneous delivery
- Viaskin Peanut
- Immune tolerance induction
Research in this area addresses both efficacy and safety in children across multiple age groups, including toddlers and school-age patients.
Pediatric Allergy
Dbv Technologies places clear emphasis on pediatric allergy, particularly in children with confirmed peanut hypersensitivity who require age-appropriate therapeutic options.
- Children aged 1 to 3 years
- Children aged 4 to 7 years
- Long-term allergy management
The sponsor’s studies span early childhood through later childhood, highlighting interest in treatment strategies suited to developmental stages and family-centered allergy care.
Allergy Safety and Tolerability
A major therapeutic theme in the sponsor’s portfolio is the safety and tolerability of allergy treatment, with attention to how children respond to prolonged therapy for food allergy.
- Treatment safety
- Long-term tolerability
- Pediatric risk management
This area includes monitoring of clinical outcomes over extended periods in children receiving treatment for peanut allergy.
